Vasoactive Intestinal Peptide as a Novel Therapeutic Strategy for Barrier Dysfunction in IBD

by Dr. James Ross

Disclaimer: All articles and product details provided on this website are intended for educational and informational purposes only. The products listed here are for in-vitro research only. In-vitro studies are conducted outside of living organisms. These products are not intended as medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. The direct or indirect administration of these substances to humans or animals is unequivocally prohibited under applicable law.

Role of VIP in Gastrointestinal Health

Vasoactive intestinal peptide (VIP) is a key regulator of gastrointestinal (GI) function. It preserves epithelial barrier stability, reduces inflammation, and promotes tolerance to gut microbes. By coordinating these activities, VIP helps sustain homeostasis throughout the GI tract.

Effects of VIP Deficiency on Microbial Ecology

Based on its functions, it was proposed that a loss of VIP would alter gut microbial communities. Studies confirmed this hypothesis: mice lacking VIP exhibited notable shifts in bacterial composition, reduced diversity, and significant weight loss compared with heterozygous or wild-type littermates. The microbial restructuring in VIP-deficient mice mirrors changes described in autoimmune and inflammatory diseases. These results indicate that VIP is essential for microbiota stability, biodiversity, and proper GI function.

Physiological Actions of VIP in the GI Tract

VIP is secreted by submucosal and myenteric neurons. It influences acid secretion in the stomach, regulates water and ion transport in the colon, reduces smooth muscle contraction to support peristalsis, and stimulates mucus release from goblet cells. VIP also maintains epithelial homeostasis by promoting cell proliferation, adhesion, and differentiation.

Metabolic and Immune Consequences of VIP Deficiency

Mice without VIP display imbalances in multiple hormones, including glucagon and leptin. Within the intestinal immune environment, VIP reduces inflammatory signaling by limiting dendritic cell activation and by generating regulatory T cells. Evidence shows that VIP-deficient mice are more susceptible to chemically induced colitis. In humans, patients with inflammatory bowel disease often have fewer VIP-positive nerves near areas of severe tissue damage.

Although VIP has mild antimicrobial activity against certain commensals, its primary role is to preserve tolerance. Altogether, VIP contributes to epithelial stability, metabolic regulation, and microbial balance. Loss of this molecule drives biodiversity collapse, microbial shifts, and weight loss.

Limited Research on VIP and Microbiota

Despite the strong links between VIP and microbiota, relatively little research has directly studied this relationship. One notable experiment demonstrated that VIP administration in piglets modified gut microbial composition and prevented diarrhea and weight loss after bacterial challenge, further supporting its protective role.

VIP and Digestive Secretions

VIP and the Exocrine Pancreas

The exocrine pancreas is influenced by neural signals that release neuropeptides such as VIP and gastrin-releasing peptide. VIP is involved in stimulating protein and bicarbonate secretion through vagal pathways.

Interaction Between VIP and Bile Acids

Bile acid infusion triggers the release of several hormones and neuropeptides, including VIP, which enhances pancreatic fluid and bicarbonate output. This effect appears dose dependent and is blocked by atropine, highlighting a cholinergic component. Comparative studies show that in cats, VIP acts as a full agonist of secretin, while in dogs it functions as a partial agonist and competitively inhibits secretin-driven pancreatic secretion. Together, VIP and secretin can synergistically boost pancreatic activity.

See more: therapeutic potential of pnc 27  

VIP and Endocrine Function

Stimulation of Insulin Secretion

Parasympathetic nerve terminals in pancreatic islets contain VIP and its related peptide PACAP. Both stimulate insulin release, underscoring their importance in glucose control and metabolic health.

VIP and Intestinal Barrier Function

VIP and Colitis Models

VIP protects epithelial integrity during bacterial infection and colitis. In experimental colitis, VIP reduced tissue injury, prevented increases in intestinal permeability, and preserved tight junction proteins such as zonula occludens-1, occludin, and claudin-3.

Molecular Mechanisms of Barrier Protection

VIP suppressed expression of myosin light chain kinase and phosphorylation of myosin light chain, mechanisms that typically drive epithelial disruption. These actions helped stabilize tight junctions and reduce bacterial-induced barrier damage.

Stress and Barrier Dysfunction

VIP also regulates barrier function during stress by acting through mast cells. In animal models, stress-induced permeability was abolished when VIP signaling was restored.

VIP Deficiency and Barrier Defects

Mice lacking VIP exhibit distorted crypts, reduced epithelial proliferation, impaired migration, increased apoptosis, and altered permeability at baseline. They also show fewer goblet cells and reduced expression of mucins and protective factors. These structural and molecular defects are linked to decreased expression of transcription factors essential for intestinal homeostasis. When challenged with chemical colitis, VIP-deficient mice developed more severe disease, while treatment with VIP restored barrier function and reduced inflammation.

Conclusion

VIP is a central regulator of gastrointestinal homeostasis. It maintains microbial balance, supports epithelial integrity, regulates hormone secretion, and prevents excessive immune activation. Deficiency results in major microbial shifts, barrier breakdown, hormonal imbalance, and heightened vulnerability to colitis. Together, these findings identify VIP as both a guardian of gut health and a potential therapeutic target in inflammatory bowel disease and related disorders.

REFERENCES

1. Riepl RL, Fiedler F, Teufel J, Lehnert P. Effect of intraduodenal bile and taurodeoxycholate on exocrine pancreatic secretion and on plasma levels of vasoactive intestinal polypeptide and somatostatin in man. Pancreas. 1994 Jan;9(1):109-16. doi: 10.1097/00006676-199401000-00016. PMID: 7509061.
2. Filipsson K, Kvist-Reimer M, Ahrén B. The neuropeptide pituitary adenylate cyclase-activating polypeptide and islet function. Diabetes. 2001 Sep;50(9):1959-69. doi: 10.2337/diabetes.50.9.1959. PMID: 11522660.
3. Keita AV, Carlsson AH, Cigéhn M, Ericson AC, McKay DM, Söderholm JD. Vasoactive intestinal polypeptide regulates barrier function via mast cells in human intestinal follicle-associated epithelium and during stress in rats. Neurogastroenterol Motil. 2013 Jun;25(6):e406-17. doi: 10.1111/nmo.12127. Epub 2013 Apr 18. PMID: 23600853.
4. Konturek SJ, Pucher A, Radecki T. Comparison of vasoactive intestinal peptide and secretin in stimulation of pancreatic secretion. J Physiol. 1976 Feb;255(2):497-509. doi: 10.1113/jphysiol.1976.sp011292. PMID: 1255530; PMCID: PMC1309260.
5. Riepl RL, Fiedler F, Teufel J, Lehnert P. Effect of intraduodenal bile and taurodeoxycholate on exocrine pancreatic secretion and on plasma levels of vasoactive intestinal polypeptide and somatostatin in man. Pancreas. 1994 Jan;9(1):109-16. doi: 10.1097/00006676-199401000-00016. PMID: 7509061.